Financial Survey: TC Biopharm (NASDAQ:TCBP) vs. Monte Rosa Therapeutics (NASDAQ:GLUE)

TC Biopharm (NASDAQ:TCBP) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Institutional & Insider Ownership

16.3% of TC Biopharm shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 15.4% of TC Biopharm shares are owned by company insiders. Comparatively, 6.5% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares TC Biopharm and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TC Biopharm	N/A	N/A	N/A
Monte Rosa Therapeutics	N/A	-74.13%	-49.14%

Risk & Volatility

TC Biopharm has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for TC Biopharm and Monte Rosa Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TC Biopharm	0	0	0	0	N/A
Monte Rosa Therapeutics	0	1	3	0	2.75

Monte Rosa Therapeutics has a consensus price target of $12.25, suggesting a potential upside of 209.34%. Given Monte Rosa Therapeutics’ higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than TC Biopharm.

Earnings & Valuation

This table compares TC Biopharm and Monte Rosa Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TC Biopharm	$4.76 million	0.88	-$7.35 million	N/A	N/A
Monte Rosa Therapeutics	N/A	N/A	-$135.35 million	($2.52)	-1.57

TC Biopharm has higher revenue and earnings than Monte Rosa Therapeutics.

Summary

TC Biopharm beats Monte Rosa Therapeutics on 5 of the 9 factors compared between the two stocks.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.